Dermapharm Holding SE

Dermapharm Holding SE’s 2025 earnings dip to €1.165 bn, yet EBITDA climbs—reflecting cost‑control and rising profit margins. Dividend cuts to €0.88 per share signal reinvestment for research and expansion, keeping the SDAX‑listed drugmaker attractiv…

Dermapharm’s 4.3 million‑share buy‑back signals confidence amid Germany’s sluggish pharma sector, aiming to boost value and counter investor doubt.

Dermapharm Holding’s insider buy by Themis Beteiligungs signals strong confidence and could boost investor confidence, liquidity, and future growth prospects.